At close: December 20 at 4:00:02 PM EST
After hours: December 20 at 4:13:48 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | 1 |
| Avg. Estimate | -0.58 | 0 | -5.08 | -2.61 |
| Low Estimate | -0.58 | 0 | -5.08 | -2.61 |
| High Estimate | -0.58 | 0 | -5.08 | -2.61 |
| Year Ago EPS | -- | -- | -- | -5.08 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 5 | 5 |
| Avg. Estimate | 60k | -- | 270.4k | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 300k | -- | 550k | -- |
| Year Ago Sales | -- | -- | -- | 270.4k |
| Sales Growth (year/est) | -- | -- | -- | -100.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 |
|---|---|---|
| EPS Est. | -1.59 | -0.63 |
| EPS Actual | -0.64 | -0.87 |
| Difference | 0.95 | -0.24 |
| Surprise % | 59.89% | -37.46% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.58 | 0 | -5.08 | -2.61 |
| 7 Days Ago | -0.64 | 0 | -4.07 | -2.49 |
| 30 Days Ago | -0.64 | 0 | -4.07 | -2.5 |
| 60 Days Ago | -0.64 | 0 | -4.07 | -2.5 |
| 90 Days Ago | -0.59 | 0 | -3.89 | -2.7 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | 1 | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ARTV | -- | -- | -- | 48.62% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 11/13/2024 |
| Reiterates | Needham: Buy to Buy | 8/30/2024 |
| Initiated | Needham: Buy | 8/13/2024 |
| Initiated | Wedbush: Outperform | 8/13/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 8/13/2024 |
| Initiated | TD Cowen: Buy | 8/13/2024 |
Related Tickers
CLYM Climb Bio Inc
1.9500
0.00%
BCAX Bicara Therapeutics Inc.
17.59
+5.96%
BOLD Boundless Bio, Inc.
2.5900
+2.78%
ACOG Alpha Cognition Inc.
4.9300
-0.60%
IPSC Century Therapeutics, Inc.
1.1000
+4.76%
MBX MBX Biosciences, Inc.
20.36
+0.44%
ZBIO Zenas BioPharma, Inc.
10.01
+2.56%
SEPN Septerna, Inc.
24.28
+3.76%
NKTX Nkarta, Inc.
2.3700
+7.73%
KYTX Kyverna Therapeutics, Inc.
4.0000
+3.36%